Lilly Evista Breast Cancer Prevention Claims Promote Unapproved Use - FDA
Executive Summary
A Lilly press release promoting Evista's efficacy in breast cancer risk reduction constitutes promotion of an unapproved new use and must be halted, FDA declared in a Dec. 23 letter to the company.